🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
EBS
$EBS
🔒 US EquitiesEmergent BioSolutions Inc
AVG HISTORICAL GAP
-3.94%
MAX GAP RECORD
-35.50%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $EBS
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$EBS
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE) |
-21.09%
|
| Apr 30, 2026 Earnings Release 2026-04-30 (AFTER CLOSE) |
+9.23%
|
| Feb 26, 2026 Earnings Release 2026-02-26 (AFTER CLOSE) |
-26.13%
|
| Oct 29, 2025 Earnings Release 2025-10-29 (AFTER CLOSE) |
+15.53%
|
| Aug 06, 2025 Earnings Release 2025-08-06 (AFTER CLOSE) |
+8.46%
|
| May 07, 2025 Earnings Release 2025-05-07 (AFTER CLOSE) |
+14.56%
|
| Mar 03, 2025 Earnings Release 2025-03-03 (AFTER CLOSE) |
-18.59%
|
| Nov 06, 2024 Earnings Release 2024-11-06 (AFTER CLOSE) |
+24.24%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
14.0%
Bullish Gaps (6)
Bearish Gaps (9)
Neutral / Flat (0)
📖 Intelligence Summary
Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗